EyeDura Initiates Preclinical Efficacy Studies to Advance Insulin-Based Treatment for Neurotrophic Keratitis
NEW YORK–(BUSINESS WIRE)–EyeDura Therapeutics Inc. (www.eyedura.com), a leader in preservative-free, topical sustained-release ophthalmic therapies, today announced initiating preclinical efficacy studies with the Singapore Eye Research Institute (SERI) towards continued development of its lead insulin-based topical eye drop treatment for neurotrophic keratitis (NK), a rare eye disease affecting approximately 71,000 patients in the U.S. “This partnership […]
Aurion Biotech Expands Leadership Team, Promoting Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer
Strategic appointments fuel global clinical and commercial development of AURN001, a transformational cell therapy with the potential to restore vision Seattle, WA; Cambridge, MA; Tokyo, Japan – 30 September – Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced the promotions of Andrew Torres, Ph.D., to Chief […]
EyeDura Initiates Preclinical Efficacy Studies to Advance Insulin-Based Treatment for Neurotrophic Keratitis
NEW YORK–(BUSINESS WIRE)–EyeDura Therapeutics Inc. (www.eyedura.com), a leader in preservative-free, topical sustained-release ophthalmic therapies, today announced initiating preclinical efficacy studies with the Singapore Eye Research Institute (SERI) towards continued development of its lead insulin-based topical eye drop treatment for neurotrophic keratitis (NK), a rare eye disease affecting approximately 71,000 patients in the U.S. “This partnership […]
DefEYE Inc. Launches as Independent Ophthalmics-Focused Company Delivering Innovative Decellularized Human Placenta-Derived Biologics for Eye Care
Emerging from Verséa Health and Backed by Industry Veterans, DefEYE, Inc. setsits sights on enhancing clinical and surgical care across ocular conditions SARASOTA, FL., October 1, 2025 — DefEYE Inc. (DefEYE), a privately held ophthalmic biologicscompany with a portfolio of decellularized biologic solutions, today announced its launch as anindependent company, effective October 1, 2025. The […]
Aurion Biotech Expands Leadership Team, Promoting Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer
Strategic appointments fuel global clinical and commercial development of AURN001, a transformational cell therapy with the potential to restore vision Seattle, WA; Cambridge, MA; Tokyo, Japan – 30 September – Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced the promotions of Andrew Torres, Ph.D., to Chief […]
Visionary Clients Driving the Future of Eye Care
At LaunchLab Partners, we are proud to support companies that are redefining what’s possible in ophthalmology. The Visionary Breakthroughs supplement in Cataract & Refractive Surgery Today and Glaucoma Today recently spotlighted three of our clients for their groundbreaking innovations: Amaros is transforming ophthalmology with precision intelligence. Their technology unifies fragmented clinical and research data into […]
EYEDURA’S SUSTAINED-RELEASE EYE DROP TECHNOLOGY WINS DOUBLE INDUSTRY HONORS
Sustained-released platform has the potential to deliver therapeutic levels for seven days and beyond, addressing key treatment challenges in eye care NEW YORK — July 15, 2025 — (Business Wire) EyeDura Therapeutics Inc. (www.eyedura.com), a developer of preservative-free sustained release ophthalmic therapies, announced that it received top recognition at two major industry forums among a […]
Amaros Closes Series A Financing, Expands Advisory Board to Accelerate Market Entry of the EvidenceEngine™ Ophthalmic AI Platform
ATHERTON, Calif.–(BUSINESS WIRE)–Amaros Inc. (www.amaros.ai), a leader in ophthalmic intelligence and the developer of AI-powered EvidenceEngine platform, today announced the successful close of its Series A financing. Backed by a select group of new and existing mission-aligned investors, the round validates Amaros’ mission to transform fragmented clinical data into real-time, actionable intelligence for eye care. […]
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif. – June 5, 2025 – (BUSINESS WIRE) Sydnexis, Inc., (www.sydnexis.com) a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company’s proprietary low-dose atropine formulation, for slowing the […]
FDA Grants Atia Vision Approval to Begin US Clinical Trial of OmniVu™ Lens System in Patients with Cataracts
The OmniVu is arevolutionary dual-optic lens designed to restore dynamic visual function by harnessing the eye’s natural accommodative mechanism while preserving its anatomical integrity. Global clinical trials show promising long-term predictability and stability in more than 75 treated eyes. CAMPBELL, Calif.–(BUSINESS WIRE)–Atia Vision, Inc., a Shifamed portfolio company, today announced it has received Investigational Device […]
